Ultralong complementarity determining regions and uses thereof

Patent metadata

Field	Value
Publication number	US-11390665-B2
Application number	US-202016742759-A
Country	US
Kind code	B2
Filing date	Jan 14, 2020
Priority date	Jan 9, 2012
Publication date	Jul 19, 2022
Grant date	Jul 19, 2022

Abstract

Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.

First claim

What is claimed:

1. A polynucleotide encoding a fusion antibody or antigen-binding fragment thereof, wherein the fusion antibody or antigen-binding fragment thereof comprises a heavy chain comprising a heavy chain variable domain wherein the heavy chain variable domain comprises a complementarity determining region 3 (CDRH3) comprising from N- to C-terminus (i) a first stalk domain comprising SEQ ID NO: 159 or 160, (ii) a knob domain, wherein at least a portion of the knob domain is replaced by a toxin, and (iii) a second stalk domain comprising SEQ ID NO: 236.

2. The polynucleotide of claim 1 , wherein the polynucleotide comprises a nucleic acid sequence encoding a linker sequence selected from (GGGGS)n (SEQ ID NO: 339) wherein n is an integer between 1 and 5, GGGSGGGGS (SEQ ID NO: 337), GGGGSGGGS (SEQ ID NO: 338), or (GSG)n (SEQ ID NO: 342) wherein n is greater than or equal to one, or a combination thereof, wherein the linker is linked to a C-terminus, an N-terminus, or both C-terminus and N-terminus of the non-antibody sequence.

3. The polynucleotide of claim 1 , wherein the polynucleotide further comprises a coding sequence for a light chain.

4. The polynucleotide of claim 3 , wherein the heavy chain and light chain are encoded in the same vector.

5. A vector comprising the polynucleotide of claim 3 .

6. A host cell comprising the vector of claim 5 .

7. A method of producing a fusion antibody or antigen-binding fragment thereof comprising an ultralong CDR3 or fragment thereof comprising culturing the host cell of claim 5 under conditions wherein the polynucleotide sequence is expressed and the fusion antibody or antigen-binding fragment thereof comprising the ultralong CDR3 or fragment thereof is produced.

8. The method of claim 7 , further comprising recovering the fusion antibody or antigen-binding fragment thereof comprising the ultralong CDR3 or fragment thereof from the host cell culture.

9. The polynucleotide of claim 1 , wherein the fusion antibody or antigen-binding fragment thereof is selected from a chimeric antibody, a human engineered antibody, a
humanized antibody, a bovine antibody, a bovinized antibody, a bovine engineered antibody, and a fully bovine antibody.

10. The polynucleotide of claim 1 , wherein the fusion antibody or antigen-binding fragment thereof comprises a Fab, a scFv, dsFv, diabody, (dsFv)2, minibody, flex minibody or bi-specific fragment.

11. A vector comprising the polynucleotide of claim 1 .

12. A host cell comprising the vector of claim 11 .

Assignees

• Scripps Research Inst

Inventors

• Smider Vaughn
• Bazirgan Omar A
• Mao Hongyuan Helen
• Schultz Peter
• Wang Feng
• Zhang Yong

Classifications

• C07K16/00 Primary

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C07K2319/55

  containing a fusion with a toxin, e.g. diphteria toxin · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2318/00

  Antibody mimetics or scaffolds · CPC title